Skip to main content

Advertisement

Table 3 Baseline characteristics in matched pairs of patients with NPC

From: Pretreatment platelet count improves the prognostic performance of the TNM staging system and aids in planning therapeutic regimens for nasopharyngeal carcinoma: a single-institutional study of 2,626 patients

Patient characteristic Group 1 ( N = 270 pairs) Group 2 ( N = 34 pairs) Group 3 ( N = 379 pairs) Group 4 ( N = 60 pairs)
RT [ n (%)] CRT [ n (%)] RT [ n (%)] CRT [ n (%)] RT [ n (%)] CRT [ n (%)] RT [ n (%)] CRT [ n (%)]
Age (years)         
≤45 138 (51.1) 138 (51.1) 18 (52.9) 18 (52.9) 171 (45.1) 171 (45.1) 31 (51.7) 31 (51.7)
>45 132 (48.9) 132 (48.9) 16 (47.1) 16 (47.1) 208 (54.9) 208 (54.9) 29 (48.3) 29 (48.3)
Sex         
Male 71 (26.3) 71 (26.3) 8 (23.5) 8 (23.5) 79 (20.8) 79 (20.8) 15 (25.0) 15 (25.0)
Female 199 (73.7) 199 (73.7) 26 (76.5) 26 (76.5) 300 (79.2) 300 (79.2) 45 (75.0) 45 (75.0)
TNM classification         
I 4 (1.5) 4 (1.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
II 266 (98.5) 266 (98.5) 34(100.0) 34 (100.0) 0 (0) 0 (0) 0 (0) 0 (0)
III 0 (0) 0 (0) 0 (0) 0 (0) 293 (77.3) 293 (77.3) 39 (65.0) 39 (65.0)
IV 0 (0) 0 (0) 0 (0) 0 (0) 86 (22.7) 86 (22.7) 21 (35.0) 21 (35.0)
T category         
T1 72 (26.7) 72 (26.7) 9 (26.5) 9 (26.5) 38 (10.0) 38 (10.0) 3 (5.0) 3 (5.0)
T2 198 (73.3) 198 (73.3) 25 (73.5) 25 (73.5) 92 (24.3) 92 (24.3) 12 (20.0) 12 (20.0)
T3 0 (0) 0 (0) 0 (0) 0 (0) 167 (44.1) 167 (44.1) 24 (40.0) 24 (40.0)
T4 0 (0) 0 (0) 0 (0) 0 (0) 82 (21.6) 82 (21.6) 21 (35.0) 21 (35.0)
N category         
N0 28 (10.4) 28 (10.4) 3 (8.8) 3 (8.8) 87 (23.0) 87 (23.0) 10 (16.7) 10 (16.7)
N1 242 (89.6) 242 (89.6) 31 (91.2) 31 (91.2) 103 (27.2) 103 (27.2) 20 (33.3) 20 (33.3)
N2 0 (0) 0 (0) 0 (0) 0 (0) 185 (48.8) 185 (48.8) 30 (50.0) 30 (50.0)
N3 0 (0) 0 (0) 0 (0) 0 (0) 4 (1.1) 4 (1.1) 0 (0) 0 (0)
  1. CRT, chemoradiotherapy; RT, radiotherapy. Group 1: early-stage disease with platelet count ≤300 × 109/L; Group 2: early-stage disease with platelet count >300 × 109/L; Group 3: locoregionally advanced disease with platelet count ≤300 × 109/L; Group 4: locoregionally advanced disease with platelet count >300 × 109/L.